This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Extensive Stage Small Cell Lung Cancer
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
-
Alabama Oncology, Birmingham, Alabama, United States, 35223
O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States, 352942
City of Hope - Phoenix, Goodyear, Arizona, United States, 85338
Arizona Clinical Research Center (ACRC), Tucson, Arizona, United States, 85715
Highlands Oncology Group, Springdale, Arkansas, United States, 72762
OPN - Oncology Physician Network, Arcadia, California, United States, 91107
Compassionate Care Research Group, Fountain Valley, California, United States, 92708
Providence Medical Foundation, Fullerton, California, United States, 92835
Los Angeles Cancer Network, Glendale, California, United States, 91204
Long Beach Memorial Medical Center, Long Beach, California, United States, 90806
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Shanghai Henlius Biotech,
2025-12-31